Checkpoint inhibitor

SELLAS Life Sciences Reports Full Year 2020 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 23, 2021
Cancer immunotherapy, Clinical medicine, Medicine, Checkpoint inhibitor, Immunotherapy, Cancer

Despite numerous challenges caused by the COVID-19 pandemic, during 2020 SELLAS remained steadfast and focused on its core mission to develop innovative cancer immunotherapies to prolong patients lives.

Key Points: 
  • Despite numerous challenges caused by the COVID-19 pandemic, during 2020 SELLAS remained steadfast and focused on its core mission to develop innovative cancer immunotherapies to prolong patients lives.
  • The fourth quarter of 2020 brought a strong close to a transformative year for SELLAS.
  • In December 2020, SELLAS announced initial data from two early stage clinical studies of GPS in combination with checkpoint inhibitor therapies.
  • About SELLAS Life Sciences Group, Inc.
    SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications.

BioNTech to Report Full Year Financial Results for 2020 and Provide Corporate Update on the Fourth Quarter on March 30, 2021

Retrieved on: 
Tuesday, March 23, 2021
Medicine, Clinical medicine, Life sciences, Cancer immunotherapy, Immune system, Biotechnology, Chimeric antigen receptor T cell, Gene therapy, Biopharmaceutical, Immunotherapy, BioNTech, Checkpoint inhibitor

A replay of the webcast will be available shortly after the conclusion of the call and archived on the Companys website for 30 days following the call.

Key Points: 
  • A replay of the webcast will be available shortly after the conclusion of the call and archived on the Companys website for 30 days following the call.
  • Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases.
  • The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals.
  • Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.

Enlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect of Allocetra™ in Combination with Immune Checkpoint Inhibitors

Retrieved on: 
Monday, March 22, 2021
Cancer immunotherapy, Medicine, Clinical medicine, Yale Cancer Center, Yale School of Medicine, Health care, Cancer, Immunotherapy, Checkpoint inhibitor, Draft:Roy S. Herbst

Allocetra is a macrophage-reprogramming immunotherapy product candidate currently in clinical development by Enlivex, as, among other things, a potential therapy in combination with approved immune checkpoint inhibitors for hard-to-treat solid tumors.

Key Points: 
  • Allocetra is a macrophage-reprogramming immunotherapy product candidate currently in clinical development by Enlivex, as, among other things, a potential therapy in combination with approved immune checkpoint inhibitors for hard-to-treat solid tumors.
  • The Principal Investigator for this collaboration is Dr. Vish Muthusamy, PhD, Director of the Yale Center for Precision Cancer Modeling.
  • The collaborations scientific advisor is Dr. Marcus W. Bosenberg, MD, PhD, Co-Leader of the Genomics, Genetics and Epigenetics Program at Yale Cancer Center.
  • Yale Cancer Center (YCC) is one of only 51 National Cancer Institute-designated comprehensive cancer centers in the nation and the only such center in Connecticut.

Ultimovacs (ULTI): Initiation - Cancer vaccine with virtually universal potential

Retrieved on: 
Wednesday, March 17, 2021
Branches of biology, DNA replication, Ribonucleoproteins, Senescence, Telomerase, Biology, Cancer, Checkpoint inhibitor, Clinical medicine

Ultimovacs is a biotechnology company focused on developing a next generation cancer vaccine with virtually universal potential.

Key Points: 
  • Ultimovacs is a biotechnology company focused on developing a next generation cancer vaccine with virtually universal potential.
  • Lead asset, UV1, activates the immune system to recognise cancer cells that express human telomerase reverse transcriptase (hTERT, or telomerase), which is present in over 85% of all cancer types.
  • For this reason, UV1 has broad potential in a variety of cancers and in combination with other treatments.
  • Ultimovacs' R&D strategy is to combine UV1 with checkpoint inhibitors (CPIs) due to an expected treatment synergy.

Oncocyte Announces Peer-Reviewed Publication of Data Assessing Use of DetermaIO™ to Identify Patients Likely to Benefit from Immunotherapy Across Multiple Tumor Types

Retrieved on: 
Tuesday, March 16, 2021
Clinical medicine, Medicine, Cancer immunotherapy, Cancer, Checkpoint inhibitor, Immunotherapy, PD-L1, Treatment of lung cancer, Lung cancer, PD-1 and PD-L1 inhibitors, Draft:Tumor Mutational Burden

Immunotherapies using immune checkpoint inhibitors (ICIs) are widely considered standard of care in the treatment of lung cancer, breast cancer, and other solid tumor types.

Key Points: 
  • Immunotherapies using immune checkpoint inhibitors (ICIs) are widely considered standard of care in the treatment of lung cancer, breast cancer, and other solid tumor types.
  • In addition, ICI therapies have been shown to cause adverse immune-related events that can be life-threatening for some patients.
  • Standard of care PD-L1 testing incorrectly identifies many patients as potential responders to immune checkpoint inhibitors, and misses certain other patients who may respond.
  • Therefore, there appears to be an unmet need for a better predictive biomarker that can identify patients that will likely benefit from ICI therapy.

UroGen Pharma Announces Sponsored Research Agreement with the Johns Hopkins University School of Medicine to Expand Immuno-Oncology Pipeline

Retrieved on: 
Monday, March 15, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, University, Education, Cancer immunotherapy, Clinical medicine, Medicine, Immune system, Branches of biology, Checkpoint inhibitor, Immunotherapy, Clusters of differentiation, CTLA-4

Johns Hopkins researchers expect to begin nonclinical research of RTGel combined with a PD-1 and a CTLA-4, respectively, in the second quarter of 2021.

Key Points: 
  • Johns Hopkins researchers expect to begin nonclinical research of RTGel combined with a PD-1 and a CTLA-4, respectively, in the second quarter of 2021.
  • Local delivery of checkpoint inhibitors has the potential to fundamentally change the treatment paradigm for some of the most devastating cancers.
  • We are excited to work with Johns Hopkins investigators on this exciting frontier in immunotherapy, said Dr. Mark Schoenberg, Chief Medical Officer of UroGen Pharma.
  • With our expanding programs in this field of research, we look forward to extending the potential of our RTGel platform in immunotherapy.

OSE Immunotherapeutics and ARCAGY - GINECO Announce Initiation of a Randomized Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer

Retrieved on: 
Monday, March 15, 2021
Clinical medicine, Cancer treatments, Medicine, Antineoplastic drugs, Cancer immunotherapy, Oncology, Breakthrough therapy, Pembrolizumab, Checkpoint inhibitor, Ovarian cancer, Cancer, Chemotherapy

Tedopi will be evaluated alone and in combination with Mercks Keytruda (pembrolizumab), an immune checkpoint inhibitor, as maintenance treatment in ovarian cancer patients after chemotherapy.

Key Points: 
  • Tedopi will be evaluated alone and in combination with Mercks Keytruda (pembrolizumab), an immune checkpoint inhibitor, as maintenance treatment in ovarian cancer patients after chemotherapy.
  • We are very pleased to collaborate with the oncology group ARCAGY GINECO to advance a new therapeutic pathway for patients suffering from a particularly aggressive cancer.
  • TEDOVA is the first trial evaluating such an innovative approach in ovarian cancer and has received enthusiastic support from the international gynecological oncology community.
  • Worldwide, ovarian cancer is the seventh most common cancer and the eighth leading cause of cancer death in women.

Replimune to Present at the American Association for Cancer Research Annual Meeting 2021

Retrieved on: 
Thursday, March 11, 2021
Clinical medicine, Medicine, Oncolytic virus, American Association for Cancer Research, Checkpoint inhibitor, Biotechnology, Experimental cancer treatments, Branches of biology, Virotherapy

WOBURN, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced two poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021 being held virtually April 10-15, 2021 and May 17-21, 2021.

Key Points: 
  • WOBURN, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today announced two poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021 being held virtually April 10-15, 2021 and May 17-21, 2021.
  • Both full posters will be available for on-demand viewing on the AACR Annual Meeting 2021 website starting at 8:30 am ET on April 10, 2021 and will also be posted to the presentations section of the Replimune website at https://ir.replimune.com/events-and-presentations/presentations .
  • Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer.
  • The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers.

Checkpoint Inhibitor Response Prediction Milestone Achieved in KIYATEC Study Detecting Ex Vivo Cancer Patient-Specific Immune Response

Retrieved on: 
Thursday, March 11, 2021
Oncology, Health, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Clinical medicine, Medical specialties, Medicine, Immune system, Cancer immunotherapy, Clusters of differentiation, Virotherapy, PD-L1, Immunotherapy, Checkpoint inhibitor, Oncology, Cancer immunology

today announced that research published in the March 2021 Cancer Immunology, Immunotherapy journal solidifies the foundation to characterize predictive accuracy in immuno-oncology.

Key Points: 
  • today announced that research published in the March 2021 Cancer Immunology, Immunotherapy journal solidifies the foundation to characterize predictive accuracy in immuno-oncology.
  • Immune checkpoint inhibitors that target programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) have only shown modest activity as monotherapies for the treatment of ovarian cancer.
  • Approval for a patients use of these immunotherapies is based on the current paradigm of cancer drug selection, spanning genetic sequencing, gene expression and biomarkers.
  • The importance of checkpoint inhibitors meeting key clinical endpoints has recently been brought into focus in more than one cancer indication.

Alpine Immune Sciences Announces Poster Presentations at AACR Virtual Annual Meeting I

Retrieved on: 
Wednesday, March 10, 2021
Oncology, Health, FDA, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Cancer immunotherapy, Clinical medicine, Medicine, Virotherapy, Immune system, American Association for Cancer Research, Immunotherapy, Checkpoint inhibitor, ALPN-202, Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the planned presentation of two posters at the American Association for Cancer Research (AACR) Virtual Annual Meeting I, taking place April 10-15, 2021.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the planned presentation of two posters at the American Association for Cancer Research (AACR) Virtual Annual Meeting I, taking place April 10-15, 2021.
  • Details of the presentations are as follows:
    Presentation Title: NEON-1: A first-in-human phase I open-label study of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies
    Titles and/or full abstracts are available on the AACR Virtual Annual Meeting website .
  • Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics.
  • Secreted Immunomodulatory Proteins, SIP, Transmembrane Immunomodulatory Protein, TIP, Variant Ig Domain, vIgD and the Alpine logo are registered trademarks or trademarks of Alpine Immune Sciences, Inc. in various jurisdictions.